Blog

The Company advocates long-term perspective as Bitcoin adoption continues to grow

MIAMI, FL / ACCESS Newswire / December 18, 2025 / Athena Bitcoin Global (OTC PINK:ABIT) (“Athena” or the “Company”), the third largest global operator of Bitcoin kiosks and digital asset fintech solutions, marks the twelfth anniversary of HODL Day on December 18 by highlighting the importance of education, long-term thinking, and informed decision-making in Bitcoin ownership.

The term “HODL” originated from a 2013 Bitcoin forum post in which user GameKyuubi misspelled the word “hold.” The term has become a well-known strategy among cryptocurrency investors, symbolizing a long-term approach to Bitcoin ownership, emphasizing patience during market volatility, and discouraging emotionally-driven panic selling.

“Long-term holding is rooted in education, risk awareness, and confidence in Bitcoin’s fundamentals, not short-term price movements,” said Matias Goldenhorn, CEO of Athena Bitcoin. “Bitcoin rewards patience and preparation. Our goal is to help people participate safely and responsibly with knowledge and a long-term mindset.”

Athena Bitcoin operates one of the largest Bitcoin ATM networks across the Americas and emphasizes user education as a core part of open and responsible access. The Company provides clear guidance at its kiosks and online to help users recognize common scams, help users understand volatility, and make informed choices aligned with their financial goals.

As Bitcoin adoption continues to grow globally, Athena remains committed to a delivering a positive customer experience by providing secure and user-friendly access to Bitcoin and enabling financial empowerment through informed and deliberate participation in a decentralized financial system.

To find the nearest Athena Bitcoin location and learn more about the promotion, customers can visit www.athenabitcoin.com

About Athena Bitcoin Global

Athena Bitcoin Global operates an international network of Athena Bitcoin kiosks, which are free standing kiosks that permit customers to buy or sell Bitcoin in exchange for fiat currencies. The Company places its machines in convenience stores, shopping centers and other easily accessible locations in thirty-four US states, Puerto Rico, and in three countries in Central and South America. Athena Bitcoin Global’s comprehensive fintech platform enables POS merchant payments powered by Athena Pay and the Company provides safe, reliable and personalized trading services through its Athena Plus services. To learn more visit www.athenabitcoin.com or follow Athena Bitcoin Global on Twitter and LinkedIn.

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by forward-looking statements as a result of various factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Athena Bitcoin Global specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Rachele Andrejczak
rachele@athenabitcoin.com

SOURCE: Athena Bitcoin Global

View the original press release on ACCESS Newswire

• In partnering with Aspire’s BUZZ BOMB™ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand’s industry-leading commitment to innovation

ESTERO, FL / ACCESS Newswire / December 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a leader in innovative supplement delivery systems, is proud to announce that professional ultra-marathoner and Ironman champion Ashley Paulson has joined Aspire as the official Brand Ambassador for BUZZ BOMB™, the Company’s premier sublingual caffeine product.

Ashley Paulson: Endurance Athlete and BUZZ BOMB™ Ambassador

Ashley Paulson is a world-class endurance athlete, coach, and inspirational fitness figure whose journey embodies resilience, consistency, and joy in movement. Since beginning marathons as a teenager, she has completed 130+ official marathons, 25+ Ironman-distance triathlons, multiple ultra triathlons, and numerous ultra marathons, including two 281.2-mile events and 6+ 100-mile races. Notably, Ashley has earned the title of 2022 Women’s Champion and 2023 Overall Champion at the iconic Badwater 135 (one of the most grueling endurance races in the world) and holds the female course record for the event.

“Ashley is the personification of high energy and relentless drive,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “We didn’t just want a face for the brand; we wanted someone who truly relies on our technology to perform at the highest level possible. Ashley is that person.”

Higginson added, “Our Ambassadors play an important role in our brand ecosystem. They not only inspire and influence athletes, but they have also demonstrated their ability to create genuine connections with their followers around the world, directly informing and elevating our performance product through their unique insights and expertise.”

Beyond her extraordinary athletic accomplishments, Ashley is a dedicated mother of four and has maintained an active role in fitness instruction and community engagement for over 20 years. She has been a group fitness instructor, a charismatic on-camera talent for major platforms such as NordicTrack/iFIT, and a mentor who inspires others to overcome personal challenges. Her philosophy, often described as “funsistency,” blends joy with relentless consistency, encouraging individuals of all levels to pursue their goals with passion and perseverance.

A New Era of Instant Energy

Traditional caffeine sources, like coffee or energy drinks, can take as long as 45 minutes to process through the digestive system. BUZZ BOMB™ utilizes a sublingual delivery method, allowing the caffeine to be absorbed directly through the tissues in the mouth for a near-instant effect without the “jitters” or digestive upset often associated with liquid supplements.

“In the middle of a 100-mile race, I don’t have time to wait for a drink to kick in, and I certainly don’t want a heavy stomach,” said Ashley Paulson. “BUZZ BOMB™ is a game-changer for my training and racing. It’s fast, portable, and gives me immediate mental clarity exactly when I’m hitting a wall. I’m excited to partner with a brand that embraces a comprehensive approach to wellness.”

The Paulson BUZZ BOMB™ Partnership

The collaboration marks a significant step for Aspire Biopharma as it expands its reach into the high-performance athletics and fitness markets.

• Authentic Performance: Ashley’s lifestyle as a mother of four and an elite athlete requires a balance of sustained energy and quick recovery.

• Scientific Innovation: BUZZ BOMB™ aligns with Ashley’s preference for “clean” performance tools that prioritize efficiency.

• Community Engagement: Paulson will lead upcoming digital campaigns, share exclusive training content, and represent BUZZ BOMB™ at major endurance events throughout 2026.

Ashley has over 174,000 followers on Instagram, 23,000 followers on TikTok, and over12,000 on Facebook. The posts, videos and stories Ashley shares on her social media platforms are considered to be in the upper tier of performance for influencer engagement. Her followers include active individuals who are interested in fitness and who appreciate Ashley’s authentic, fun, and open communication style.

For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.

https://www.instagram.com/ashkickn/?hl=en,

https://www.tiktok.com/@ashkickn1

https://www.facebook.com/ashley.j.paulson/

About BUZZ BOMB™

BUZZ BOMB™ is a proprietary sublingual caffeine supplement developed by Aspire Biopharma that features 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha). Designed for athletes, professionals, and anyone needing a rapid cognitive boost, BUZZ BOMB^® provides a precise dose of caffeine that bypasses the GI tract for faster onset and smoother energy.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver supplements to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

November sales reach $2.05 million with ~30% gross margins

WEST SENECA, NY / ACCESS Newswire / December 18, 2025 / Worksport Ltd. (NASDAQ:WKSP) (“Worksport” or the “Company”), a U.S.-based innovator in advanced manufacturing, clean energy technologies and automotive accessories, serving both consumer and reseller markets, today reported record monthly sales for November 2025, continuing the Company’s strong revenue growth trend and margin expansion.

The Company achieved unaudited net sales of approximately $2.05 million in November, representing the highest monthly revenue in Worksport’s history. Gross margin for the month was approximately 30%, reflecting continued operational improvements and manufacturing scale.

This performance builds on a clear and consistent growth trajectory throughout 2025. Monthly revenue increased from approximately $1.2 million in April, to $1.71 million in July, and now to more than $2.0 million in November. Management believes this trend reflects growing product demand, improved production efficiency, and stronger pricing discipline.

Margin expansion has also remained a key focus. Gross margin improved from approximately 11% in Q4 2024, to 18% in Q1 2025, 26% in Q2 2025, and now near 30%. The Company believes these gains demonstrate the effectiveness of its U.S. manufacturing strategy and ongoing cost optimization initiatives.

“Our November results reflect real operating progress,” said Steven Rossi, Chief Executive Officer of Worksport. “Sales reached an all-time monthly record with margins remaining stable and expected to grow. We believe this shows that our business model is scaling, demand remains strong, and our execution is improving quarter by quarter.”

Management noted that the Company continues to execute on disciplined growth initiatives, drive operating efficiencies, and expand sales of its clean-energy products, including the recently announced SOLIS and COR systems, while sustaining steady demand across its core tonneau cover lineup.

Worksport expects to continue providing updates as it advances toward sustained profitability and long-term shareholder value creation.

Join Worksport’s Investor Relation Newsletter for all Future Updates: Worksport’s Newsletter.

Contacts

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789-128
W: investors.worksport.com W: www.worksport.com E: investors@worksport.com

Connect with Worksport Chief Executive Officer, Steven Rossi

Steven Rossi X (Twitter)
Steven Rossi LinkedIn

About Worksport

Worksport Ltd. (Nasdaq:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport’s hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy’s website is terravisenergy.com.

Connect with Worksport

Please follow the Company’s social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram, the links of which are links to external third-party websites, as well as sign up for the Company’s newsletters at investors.worksport.com.

Social Media Disclaimer

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission (SEC”) filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “scheduled,” “expect,” “future,” “intend,” “plan,” “project,” “envisioned,” “should,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

SOURCE: Worksport Ltd.

View the original press release on ACCESS Newswire

MIAMI BEACH, FLORIDA / ACCESS Newswire / December 18, 2025 / LQR House Inc. (the “Company” or “LQR House”) (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, today announced that it has entered into securities purchase agreements with new and existing investors and certain directors and officers of the Company, for the purchase and sale of 7,249,972 shares of common stock at a purchase price of $0.90 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $6.52 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about December 19, 2025, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds for the repayment of certain amounts owed in connection with existing settlement obligations, related litigation fees and expenses, with any remaining balance of the next proceeds for working capital and general corporate purposes.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-282118) which became effective on September 20, 2024. The offering is made only by means of a prospectus which is part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website located at http://www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About LQR House Inc.

LQR House intends to become a prominent force in the wine and spirits e-commerce sector, epitomized by its flagship alcohol marketplace, cwspirits.com. This platform seamlessly delivers a diverse range of emerging, premium, and luxury spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Functioning as a technology-driven hub, LQR House utilizes software, data analytics, and artificial intelligence to elevate consumer experience. CWSpirits.com stands out as the go-to destination for modern, convenience-oriented shoppers, providing a curated selection of alcohol products delivered to homes across the United States. Beyond its role in an e-commerce sector, LQR House is a marketing agency with a specialized focus on the alcohol industry. The Company measures campaign success by directly correlating it with sales on CWSpirits.com, demonstrating a return on investment. Backed by an influential network of around 460 figures in the alcohol space, LQR House strategically drives traffic to CWSpirits.com, enhancing brand visibility. LQR House intends to disrupt the traditional landscape of the alcohol industry, driven by its dedication to providing an unparalleled online purchasing experience and delivering tailored marketing solutions.

Forward-Looking Statements:

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the headings “Risk Factors”. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release.

Investor and Media Contact:
info@lqrhouse.com

SOURCE: LQR House

View the original press release on ACCESS Newswire

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.

MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir).

The studies were conducted as part of the Company’s ongoing IND-enabling program and evaluated cardiovascular, respiratory, phototoxicity, and repeat-dose toxicology using a combination of in vitro systems and in vivo rat and dog models. While final quality assurance (QA) review of the study reports is ongoing, the Company does not expect the overall conclusions to change.

Key Safety Findings

• Overall Safety:
  Telomir-1 was well tolerated across all completed GLP safety studies, with no treatment-related adverse or dose-limiting toxicities observed.

• Cardiovascular Safety:
  In non-rodent studies, including in dogs, no test-article-related changes in blood pressure, heart rate, electrocardiogram (ECG) parameters, or body temperature were observed following oral administration. In addition, no concerning cardiac safety signals were identified in a validated GLP assay commonly used to assess arrhythmia risk.

• Repeated-Dose Toxicology:
  Repeated oral administration in both rats and dogs were well tolerated. Observed findings were limited, reversible, and considered non-adverse, with no serious toxicological findings identified.

• Respiratory Safety:
  No clinically meaningful effects on respiratory function were observed.

• Phototoxicity:
  Telomir-1 demonstrated no evidence of phototoxic potential under simulated sunlight conditions.

Across oral administration studies, Telomir-1 demonstrated consistent systemic exposure and predictable pharmacokinetic behavior, supporting continued advancement toward clinical development.

Overall Conclusion

Collectively, these IND-enabling GLP data demonstrate a favorable safety and tolerability profile and consistent systemic exposure upon oral administration for Telomir-1. No treatment-related adverse toxicity was observed, and no findings were identified that would preclude advancement into first-in-human clinical studies, subject to applicable regulatory pathways.

CEO Perspective

“Safety is often the factor that determines whether a drug program can advance,” said Erez Aminov, Chief Executive Officer of Telomir. “Many development programs encounter safety limitations that prevent clinical progression. Achieving a broad IND-enabling GLP safety profile with no treatment-related adverse toxicity observed is a critical milestone as we prepare Telomir-1 for first-in-human evaluation.”

Scientific Perspective

“In oncology, therapeutic activity must be balanced against tolerability, as safety limitations frequently constrain dosing, duration of therapy, and patient quality of life,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “The GLP safety profile observed with Telomir-1, together with its consistent pharmacologic behavior and good oral absorption across studies, supports continued advancement into first-in-human clinical evaluation, pending regulatory review.”

Next Steps

Telomir plans to continue advancing Telomir-1 through its IND-enabling activities and broader regulatory preparations. In parallel, the Company is conducting ongoing preclinical animal model studies evaluating Telomir-1 across multiple oncology and age-related disease settings, including triple-negative breast cancer, to further characterize its biological activity and therapeutic potential.

In addition, Telomir is actively preparing scientific manuscripts for publication submission and is targeting abstract submissions and presentations at multiple oncology-focused scientific conferences in 2026, as part of its ongoing efforts to share data and engage with the scientific and clinical research community.

Based on current expectations and subject to regulatory review and other factors, the Company anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026 and initiating first-in-human clinical studies in the first half of 2026.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical biotechnology company developing small-molecule therapeutics designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative disease. The Company’s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure

Partnership strengthens global preparedness against a significant pandemic threat

If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing

OSLO, NORWAY and CAMBRIDGE, MA / ACCESS Newswire / December 18, 2025 / The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure. The funding marks a significant step forward in global pandemic preparedness that could enable fast, equitable access to vaccines for one of the world’s most pressing health threats.

This Phase 3 study would be the first mRNA-based vaccine targeting pandemic influenza to enter a pivotal trial. If the vaccine candidate is licensed, it would expand the current global portfolio of H5 vaccines with a rapid-response platform that could revolutionize future pandemic responses, making a significant contribution to CEPI’s 100 Days Mission, a global goal to develop safe and effective vaccines within 100 days of a new pandemic threat being identified.

Dr Richard Hatchett, Chief Executive Officer of CEPI said:

“Pandemic influenza remains one of the greatest threats to global health security. With this partnership, we are not just advancing vaccine science, we are fundamentally changing the game. By harnessing the speed and adaptability of mRNA technology, we could shave months off the response time, deliver vaccines at scale, and enable equitable access for all. This is how we plan to protect the world from the next flu pandemic.”

Stéphane Bancel, Chief Executive Officer of Moderna said:

“We are proud to have the support of CEPI to advance our pandemic influenza vaccine candidate, research that is critical to our commitment to pandemic preparedness. mRNA technology can play a vital role in addressing emerging health threats quickly and effectively, and we look forward to continuing our partnership with CEPI as we advance our health security portfolio, and in parallel, further the 100 Days Mission.”

A potential first-in-class mRNA vaccine for pandemic influenza

Conventional influenza vaccines require virus growth in eggs or cell culture, a process that can take months. By contrast, an mRNA vaccine can be designed in hours or days as soon as the virus’s genetic sequence is known and swiftly manufactured at scale. The combination of speed, adaptability and scalability offered by mRNA technology is a potential critical advantage when a new pandemic strain emerges and every day that passes could cost lives.

If licensure is granted, Moderna is committed to working to provide people around the world with rapid, equitable access to the resulting H5 vaccine in the event of a pandemic. As part of this agreement, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing.

The Phase 3 trial, set to begin early in 2026, will evaluate the safety and immunogenicity of Moderna’s H5 vaccine candidate in populations in the UK and U.S. It will build upon positive Phase 1/2 results which showed rapid and persistent immune responses in healthy adults aged 18 years and older. Potential licensure of the vaccine will also leverage data from a pivotal Phase 3 trial of Moderna’s investigational seasonal influenza vaccine, mRNA-1010.

This project is part of CEPI and Moderna’s strategic partnership, which aims to harness Moderna’s mRNA platform to accelerate epidemic and pandemic vaccine development.

ENDS

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 70 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ to accelerate the time taken to develop safe, effective and accessible vaccines against new threats to just 100 days. Learn more at CEPI.net.  

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: CEPI’s investment to advance Moderna’s H5 pandemic influenza vaccine candidate; the potential for licensure of mRNA-1018; the safety and immunogenicity of mRNA-1018; the potential for mRNA technology to effectively address emerging health threats; and Moderna’s ability to manufacture at scale. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

CEPI Media Contacts

Email: press@cepi.net
Phone: +44 7387 055214

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

AI-powered voice technology streamlines the leasing journey, bringing Wasatch’s long-standing innovation ethos into a new era of operational efficiency.

SALT LAKE CITY, UT / ACCESS Newswire / December 18, 2025 / Wasatch Property Management announced today the rollout of its fully integrated AI voice agent, marking a major milestone in modernizing the multifamily prospect experience. Among the first major multifamily companies to combine AI voice technology with a friction-free prospect experience, Wasatch’s new solution is designed to answer live prospect calls instantly, capture lead details accurately, and schedule tours in real time, dramatically reducing missed opportunities and enhancing operational efficiency.

Developed in partnership with Hexcode AI, the system represents a fully embedded voice experience that integrates directly with Yardi CRM IQ, enabling Wasatch communities to deliver consistent, high-quality service 24/7. Leading the industry in operational AI adoption, the voice agent handles live prospect calls, captures lead data automatically, and converts in real time, giving leasing teams more time to focus on personalized, in-person engagement.

As part of its long-standing commitment to innovation, Wasatch introduced this rollout under its broader internal initiative, Wasatch AIM (Artificial Intelligence for Multifamily) a reflection of the company’s decades-long emphasis on leveraging forward-thinking systems to enhance service, efficiency, and the resident experience.

“Voice is still the most important touchpoint in our industry, and too often it’s the most inconsistent,” said Kainoa Clark, Chief Marketing Officer for The Wasatch Group. “Rolling out a fully integrated AI voice agent allows us to meet prospects exactly where they are instantly, reliably, and with the same elevated service we expect from every Wasatch experience. This isn’t about replacing people; it’s about empowering our teams, improving responsiveness, and creating a seamless first impression that sets the tone for a great resident relationship.”

The Hexcode AI platform enables Wasatch’s agent to answer calls, qualify leads, provide real-time availability, and book tours without delays or hold time, even during peak call periods or after hours. For multifamily operations-where 40-60% of prospect calls often go unanswered across the industry-this innovation represents a significant step forward in reducing friction and maximizing conversions.

“We’re thrilled to partner with Wasatch Property Management, a company that consistently pushes the industry forward,” said Kelly Taylor, Founder and CEO of Hexcode AI. “Wasatch’s commitment to innovation and resident-first solutions made them the ideal partner for a fully integrated voice platform. Their teams aren’t just adopting AI-they’re operationalizing it in a way that redefines what great leasing service looks like.”

With the rollout now underway across multiple communities, Wasatch expects to see improvements in lead capture accuracy, call response times, appointment scheduling rates, and overall prospect satisfaction.

“As we continue to invest in technology that enhances service and builds trust, our goal remains the same,” Clark added. “A Wasatch experience should be intuitive, human-centered, and exceptionally efficient-AI just enables us to deliver that promise at scale.”

About Wasatch Property Management

Wasatch Property Management is an award-winning multifamily housing provider with communities across the Western United States encompassing over 18,000 units. With a focus on exceptional service, innovative systems, and resident-centered experiences, Wasatch continues to set the standard for quality housing, operational excellence, and forward-thinking industry leadership. Visit www.isyourhome.com

About Hexcode AI

Hexcode AI is a pioneering conversational technology company specializing in enterprise-grade voice automation for inbound and outbound sales. Designed for seamless integration and real-time workflow execution, Hexcode AI enables companies to deliver friction-free prospect experiences that convert. To learn more visit www.hexcode.ai

Contact Information

Kainoa Clark
Chief Marketing Officer
kainoa.clark@netwasatch.com
801-473-2119

SOURCE: The Wasatch Group

View the original press release on ACCESS Newswire